Neuclone Reports Dosing of NeuLara (biosimilar- ustekinumab) in P-I Trial
Shots:
- The P-I trial involves assessing of Stelara (US or EU) vs NeuLara in 210 patients in ratio (1:1:1) and resulted in no serious adverse events with anticipated results in Q3’20
- NeuLara is one of the biosimilars developed in collaboration with NeuClone and Serum Institute of India Pvt Ltd (Serum Institute). In 2009- Stelara was launched in the US and its Wholesale Acquisition Cost (WAC) increased by 136%
- NeuClone has a pipeline of biosimilars referencing Herceptin- Stelara- Synagis- Prolia/XGEVA- Perjeta and Humira developed using its NeuMAX platform
Click here to read full press release/ article | Ref: Neuclone | Image: Signbox
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com